Sökning: "FARMACI Biofarmaci"

Visar resultat 26 - 30 av 36 avhandlingar innehållade orden FARMACI Biofarmaci.

  1. 26. Intestinal absorption of drugs : The impact of regional permeability, nanoparticles, and absorption-modifying excipients

    Författare :Carl Roos; Hans Lennernäs; Erik Sjögren; Martin Brandl; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Permeability; intestinal absorption; regional permeability; nanoparticles; nanosuspensions; absorption-modifying excipients; AMEs; Biofarmaci; Biopharmaceutics;

    Sammanfattning : For successful delivery of orally given drug products, the drug compounds must have adequate solubility and permeability in the human gastrointestinal tract. The permeability of a compound is determined by its size and lipophilicity, and is usually evaluated in various pre-clinical models, including rat models. LÄS MER

  3. 27. Intestinal Permeability and Presystemic Extraction of Fexofenadine and R/S-verapamil

    Författare :Christer Tannergren; Hans Lennernäs; Dirk KF Meijer; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Biopharmacy; Bioavailability; Fexofenadine; Verapamil; P-glycoprotein; CYP3A4; OATP; Enantioselective; Permeability; Caco-2; Intestinal perfusion; Biofarmaci; Biopharmacy; Biofarmaci;

    Sammanfattning : The main objective of this thesis was to investigate the in vivo relevance of membrane transporters and cytochrome P450 (CYP) 3A4-mediated metabolism in the intestine and liver for the bioavailability of drugs in humans after oral administration.In the first part of the thesis, the main transport mechanisms involved in the intestinal absorption and bioavailability were investigated for fexofenadine, a minimally metabolized drug, which is a substrate for P-glycoprotein (P-gp) and members of organic anion transporting polypeptide (OATP) family. LÄS MER

  4. 28. First-pass Intestinal Metabolism of Drugs : Experiences from in vitro, in vivo and simulation studies

    Författare :Helena Anna Thörn; Hans Lennernäs; Paul Alfred Dickinson; Brian Houston; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacokinetics; metabolism; CYP3A4; CYP2C9; CYP2D6; UGT; glucuronidation; physiologically based pharmacokinetic model; modelling; Biopharmaceutics; Biofarmaci;

    Sammanfattning : The bioavailability of a drug can be described as the fraction of an orally administered dose that reaches the systemic circulation and is often limited by first-pass metabolism in the gut and the liver. It is important to have knowledge about these processes since the systemic blood drug concentration is tightly connected to the effect of the drug. LÄS MER

  5. 29. In vitro and in silico Predictions of Hepatic Transporter-Mediated Drug Clearance and Drug-Drug Interactions in vivo

    Författare :Anna Vildhede; Per Artursson; Maria Karlgren; Maria Kjellsson; Ulf Norinder; Kim Brouwer; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; OATP1B1; OATP1B3; OATP2B1; NTCP; drug transporters; human hepatocytes; atorvastatin; pitavastatin; proteomics; sandwich-cultured human hepatocytes; SCHH; mechanistic modeling; in vitro-in vivo extrapolation; transport inhibition; hepatic uptake; hepatocyte isolation; transporter contribution; Biopharmaceutics; Biofarmaci;

    Sammanfattning : The liver is the major detoxifying organ, clearing the blood from drugs and other xenobiotics. The extent of hepatic clearance (CL) determines drug exposure and hence, the efficacy and toxicity associated with exposure. Drug-drug interactions (DDIs) that alter the hepatic CL may cause more or less severe outcomes, such as adverse drug reactions. LÄS MER

  7. 30. Discovery of N-hydroxyguanidines as novel electron acceptors of xanthine oxidase : Potential new drugs for treatment of ischemia and reperfusion injury

    Författare :Maija Dambrova; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmaceutical biosciences; xanthine oxidase; N-hydroxyguanidine derivatives; ischemia and reperfusion; reduction; inhibition; superoxide; Farmaceutisk biovetenskap; Biopharmacy; Biofarmaci; galenisk farmaci; Pharmaceutics;

    Sammanfattning : Xanthine oxidase (EC 1.1.3.22) is one of the major enzymatic sources of oxygen-derived free radicals. LÄS MER